Nivo-lution in mesothelioma

Aaron S. Mansfield, Marjorie G. Zauderer

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.

Original languageEnglish (US)
Pages (from-to)5438-5440
Number of pages3
JournalClinical Cancer Research
Issue number18
StatePublished - Sep 15 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Nivo-lution in mesothelioma'. Together they form a unique fingerprint.

Cite this